G Model
JJCC-1450; No. of Pages 7 Journal of Cardiology xxx (2016) xxx–xxx
Contents lists available at ScienceDirect
Journal of Cardiology journal homepage: www.elsevier.com/locate/jjcc
Review
Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship Christos A. Goudis (MD, MSc, PhD)* Cardiology Department, Serres General Hospital, Serres, Greece
A R T I C L E I N F O
A B S T R A C T
Article history: Received 10 December 2016 Accepted 21 December 2016 Available online xxx
Chronic obstructive pulmonary disease (COPD) is independently associated with atrial fibrillation (AF). Decreased oxygenation, hypercapnia, pulmonary hypertension, diastolic dysfunction, oxidative stress, inflammation, changes in atrial size by altered respiratory physiology, increased arrhythmogenicity from nonpulmonary vein foci commonly located in the right atrium, and respiratory drugs have been implicated in the pathogenesis of AF in COPD. The understanding of the relationship between COPD and AF is of particular importance, as the presence of the arrhythmia has significant impact on mortality, especially in COPD exacerbations. On the other hand, COPD in AF is associated with AF progression, success of cardioversion, recurrence of AF after catheter ablation, and increased cardiovascular and allcause mortality. Treatment of the underlying pulmonary disease and correction of hypoxia and acid-base imbalance represents first-line therapy for COPD patients who develop AF. Cardioselective b-blockers are safe and can be routinely used in COPD. In addition, AF ablation was proved to be efficient and safe, and improves quality of life in these patients. This review presents the association between COPD and AF, describes the pathophysiological mechanisms implicated in AF development in COPD, underlines the prognostic significance of AF in COPD patients and vice versa, and highlights emerging therapeutic approaches in this setting. ß 2017 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Keywords: Chronic obstructive pulmonary disease Atrial fibrillation Pathophysiological mechanisms Prognosis Treatment
Contents Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Chronic obstructive pulmonary disease and atrial fibrillation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pathophysiological mechanisms implicating chronic obstructive pulmonary disease in atrial fibrillation . . Respiratory drugs and atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Prognostic significance of atrial fibrillation in chronic obstructive pulmonary disease and vice versa . . . . . Antiarrhythmic therapy and interventions for atrial fibrillation in chronic obstructive pulmonary disease. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Conflict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Introduction Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide [1]. The overall prevalence in men aged 30 years or more is 14.3% (95% CI: 13.3– 15.3%) compared to 7.6% (95% CI: 7.0–8.2%) in women [2]. COPD is
* Correspondence to: Department of Cardiology, Serres General Hospital, 45110 Serres, Greece. Fax: +30 2321094341. E-mail address:
[email protected]
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
. . . . . . . . .
000 000 000 000 000 000 000 000 000
currently rated the fourth most common specific cause of death globally and predicted to be the third by 2030, in the absence of interventions that address the risks – especially tobacco smoking, exposures to combustion products of biomass fuels, and environmental pollution [2]. Atrial fibrillation (AF) is the commonest arrhythmia in clinical practice and is associated with increased cardiovascular morbidity and mortality [3,4]. COPD has been independently associated with AF [5–16], but the precise pathophysiological mechanisms are complex and not completely understood. The presence of AF in COPD patients impairs prognosis, while the presence of COPD in AF patients also seems
http://dx.doi.org/10.1016/j.jjcc.2016.12.013 0914-5087/ß 2017 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Please cite this article in press as: Goudis CA. Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. J Cardiol (2017), http://dx.doi.org/10.1016/j.jjcc.2016.12.013
G Model
JJCC-1450; No. of Pages 7 C.A. Goudis / Journal of Cardiology xxx (2016) xxx–xxx
2
to have a specific impact on AF progression, success of cardioversion, ablation outcomes, and mortality. Specific medications and therapeutic implications may improve prognosis in this population. The present review provides a concise overview of the association between COPD and AF, and describes the arrhythmogenic mechanisms in this setting. Prognosis, as well as therapeutic implications, is also discussed. Chronic obstructive pulmonary disease and atrial fibrillation An accumulating body of evidence indicates that COPD is associated with AF [5–16]. The Copenhagen City Heart Study reported that reduced forced expiratory volume in one second (FEV1) is an independent predictor of AF onset [5]. In the ARIC study, after multivariable adjustment for traditional cardiovascular disease risk factors and height, hazard ratios (HRs) of AF comparing the lowest with the highest quartile of FEV1 were 1.37 (95% CI: 1.02–1.83) for white women, 1.49 (95% CI: 1.16–1.91) for white men, 1.63 (95% CI: 1.00–2.66) for black women, and 2.36 (95% CI: 1.30–4.29) for black men [9]. The Malmo Preventive Project, the largest to date population-based cohort study reported that after adjustment for age, height, weight, current smoking status, systolic blood pressure, erythrocyte sedimentation rate, and fasting blood glucose, FEV1 was inversely related to incidence of AF {HR: 1.39 [95% confidence interval (CI): 1.16–1.68; p = 0.001] for women, and HR: 1.20 (95% CI: 1.13–1.29; p < 0.0001) for men} [10]. Forced vital capacity (FVC) was also inversely related to
incidence of AF [HR: 1.20 (95% CI: 1.03–1.41; p = 0.020) for women, and HR: 1.08 (95% CI: 1.02–1.14; p = 0.01) for men] [10]. Similar findings were reported in the Multi-Ethnic Study of Atherosclerosis-Lung Study, which found that FEV1 and FVC are associated with a higher risk for AF (HRs 1.21 and 1.19 per 500 ml, respectively, p < 0.001) after adjustment for demographic and cardiovascular risk factors [11]. In a recent study, Konecny et al. reported that COPD was associated with increased likelihood of AF/atrial flutter (23.3% vs. 11.0%, respectively, p < 0.0001), compared to patients without COPD [12]. COPD has also been associated with postoperative AF [13–15]. In acute exacerbations of COPD, impaired pulmonary function, hypercapnia, and high values of pulmonary artery systolic pressure, were proven to be independent predictors of incident AF [16]. A summary of the published studies reporting the association between COPD and AF is provided in Table 1. Pathophysiological mechanisms implicating chronic obstructive pulmonary disease in atrial fibrillation Studies investigating the effects of hypoxia on atrial electrophysiology have yielded divergent results. In experimental models, Krause et al. observed no atrial electrophysiologic effects and no increase in AF vulnerability in the setting of profound hypoxemia [17]. Similar findings were reported by Stevenson et al. who failed to show an effect of hypoxia on either atrial refractoriness or atrial conduction. Their findings point against a direct electrophysiologic
Table 1 Studies demonstrating association between COPD and AF. Author (year)
No. of pts
Type of study
Follow-up
Buch et al. [5] (2003)
13,430
Prospective
Mapel et al. [7] (2005)
70,679
Retrospective
Shibata et al. [8] (2011)
2917
Prospective
1 yr
Johnson et al. [10] (2014)
28,744
Prospective
24.8 yrs
Li et al. [9] (2014)
15,004
Prospective
17.5 yrs
Konecny et al. [12] (2014)
7441
Retrospective
9 yrs
Terzano et al. [16] (2014)
193
Prospective
1 yr
Chahal et al. [11] (2015)
6814
Prospective
4.1 yrs
Mita et al. [15] (2016)
116
Prospective
Gec¸men et al. [13] (2016)
94
Prospective
Cerit et al. [14] (2016)
106
Retrospective
5 yrs
Results/findings Risk of new AF at re-examination was 1.8-times higher for FEV1 between 60–80% of predicted compared with FEV1 80% after adjustment for sex, age, smoking, blood pressure, diabetes and body mass index Among COPD patients, the prevalence of AF was very high (14.3%) and significantly higher than among the matched non-COPD cohort (10.4%; p < 0.001) FEV1 and FVC are independent risk factors for AF (independent of age, gender, left ventricular hypertrophy and serum levels of B-type natriuretic peptide) FEV1 was inversely related to incidence of AF [HR: 1.39 (95% CI: 1.16–1.68; p = 0.001) for women, and HR: 1.20 (95% CI: 1.13–1.29; p < 0.0001) for men]. FVC was also inversely related to incidence of AF [HR: 1.20 (95% CI: 1.03–1.41; p = 0.020) for women, and HR: 1.08 (95% CI: 1.02–1.14; p = 0.01) for men] After multivariable adjustment for traditional cardiovascular disease risk factors and height, HRs of AF comparing the lowest with the highest quartile of FEV1 were 1.37 (95% CI: 1.02–1.83) for white women, 1.49 (95% CI: 1.16–1.91) for white men, 1.63 (95% CI: 1.00– 2.66) for black women, and 2.36 (95% CI: 1.30–4.29) for black men. Moderate/severe airflow obstruction (FEV1/FVC < 0.70 and FEV1 < 80% of predicted value) was also associated with higher AF incidence The presence and severity of COPD were associated with increased likelihood of AF/AFL (23.3% vs. 11.0%, respectively, p < 0.0001), compared to pts without COPD. COPD remained a significant predictor of AF/AFL (p < 0.0001) after adjusting for age, gender, tobacco use, obesity, hypertension, coronary artery disease, heart failure, diabetes, anemia, cancer, chronic kidney disease, and rate/rhythm control medications In pts with COPD exacerbations, the prevalence of AF was higher with lower FEV1 (57.1% 7.5 vs. 76% 8.3; p < 0.05). In addition, AF was more frequent in pts with higher levels of PaCO2 (70.6 mmHg 5.3 vs. 50.1 mmHg 3.5; p < 0.05) and higher values of PASP (45.3 mmHg 3.5 vs. 35.2 mmHg 2.3; p < 0.05) Lower levels of FEV1 and FVC were associated with a higher risk for AF (HRs 1.21 and 1.19 per 500 ml, respectively, p < 0.001) after adjustment for demographic and cardiovascular risk factors Pts undergoing elective lobectomy with lymph node dissection for lung cancer. Multivariate analysis revealed COPD as risk factor for POAF To evaluate the value of SYNTAX score to predict POAF in pts undergoing CABG. An independent association was identified with COPD and POAF [b: 2.222, p: 0.003, OR: 9.228, 95% CI (2.150–39.602)] To assess the relationship between SYNTAX score and development of AF after CABG. In logistic regression analysis COPD (OR = 19.313, 95% CI: 2.416–154.407, p = 0.005) appeared as an independent variable predicting the development of POAF
COPD, chronic obstructive pulmonary disease; AF, atrial fibrillation; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; POAF, postoperative atrial fibrillation; SYNTAX, synergy between percutaneous coronary intervention with Taxus and cardiac surgery (scoring system evaluating the complexity of the lesions in coronary angiography); CABG, coronary artery bypass grafting; HR, hazard ratio; OR, odds ratio; CI, confidence interval; AFL, atrial flutter; pts, patients.
Please cite this article in press as: Goudis CA. Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. J Cardiol (2017), http://dx.doi.org/10.1016/j.jjcc.2016.12.013
G Model
JJCC-1450; No. of Pages 7 C.A. Goudis / Journal of Cardiology xxx (2016) xxx–xxx
effect of hypoxia, but an indirect effect on arrhythmiogenesis through sympathetic activation cannot be excluded [18]. On the other hand, Lammers et al. reported that in isolated superfused rabbits, the higher vulnerability of the atrium for reentrant arrhythmias by hypoxia is based on a combination of a moderate shortening of the wavelength and an increase in inhomogeneity in conduction of premature wavefronts [19]. Hypoxia-induced vascular endothelial growth factor (VEGF) expression is strongly regulated by hypoxia-inducible factor-1a (HIF-1a), the transcriptional factor for VEGF, which is a critical modulator for sensing and responding to changes in the oxygen concentration [20]. MMP-9 expression increases in fibrillating atria, and may contribute to atrial structural remodeling of AF [20]. It is possible that upregulation of HIF-1a/VEGF is involved in the enhancement of MMP-9 expression under hypoxic conditions [20]. Xu et al. reported increased levels of Toll-like receptor 2 (TLR2), HIF-1a, and MMP-9 in patients with persistent and permanent AF, and suggested that TLR2 and HIF-1a may promote left atrial structural remodeling [21]. In the same line, Su et al. reported that HIF-1a promotes the expression of TGF-b1 and MMP-9 protein, and thus is involved in atrial fibrosis [22]. QTc was also found to be prolonged in COPD patients compared to controls [23,24]. Sievi et al. reported that one third of a typical COPD population has altered cardiac repolarization and increased dispersion of repolarization, which may be related to hypoxia [24]. The ARIC study examined prolonged QT interval corrected by using the Framingham formula (QTc) as a predictor of incident AF, and showed that prolonged QTc predicts a roughly 2-fold increased risk of AF [25]. QTc interval reflects the atrial effective refractory period (AERP), suggesting that QTc interval may be used as a marker of atrial refractoriness relevant to assessing AF risk and mechanism-specific therapeutic strategies [26]. Hypercapnia has also been implicated in AF occurrence in COPD. Hypercapnia produces a marked and uniform increase in atrial refractoriness and a significant slowing in atrial conduction [18]. Return of CO2 to normal results in rapid return of refractoriness to baseline levels but conduction slowing persists, suggesting that hypercapnia may create the substrate for AF after correction [18]. Moreover, hypercapnia and hypoxemia produce pulmonary arteriolar constriction leading to pulmonary arterial and right ventricular hypertension. Right ventricular hypertension may induce arrhythmias by leading to right atrial dilatation and increasing transmural pressure on endocardial vessels altering the distribution of blood flow [16]. In COPD exacerbations, AF is more frequent with higher levels of PaCO2 and higher values of pulmonary artery systolic pressure [16]. The notion that prolonged and inhomogeneous propagation of depolarization could be present in the atria of patients with COPD has recently emerged. Right atrial electromechanical delay is significantly prolonged and negatively correlated with FEV1, while the duration of atrial depolarization is significantly prolonged in COPD patients [27]. In a recent study, Acar et al. showed that prolongation of atrial electromechanical delay measured from lateral tricuspid annulus is independently related with FEV1/FVC ratio [28]. P wave dispersion (PWD) – the difference in maximum and minimum duration of the P wave – was also found to be an independent risk factor for AF development [29]. PWD was more increased in the acute phase than in stable phase and was greater in patients with more frequent exacerbations suggesting that the PWD could be a target for prediction, prevention, and therapy of acute exacerbations of COPD [30]. P-wave duration and PQ interval were also reported to be risk factors for AF development in patients with P pulmonale, and P-wave duration is highly correlated with PQ interval >150 ms [31]. On the contrary, Buzea et al. reported that in patients with acute COPD exacerbations, P-wave signal averaged electrocardiography (SAECG) analysis and atrial late
3
potentials detection seem to have little value in the arrhythmic risk evaluation [32]. COPD contributes to ventricular diastolic dysfunction [33– 35]. Left ventricular diastolic dysfunction is associated with disease severity, and may serve as another possible pathophysiological mechanism for AF initiation and perpetuation [33–35]. In addition, right ventricular systolic dysfunction and elevated systolic pulmonary artery pressure are independently associated with right atrium volume index in patients with pulmonary hypertension due to COPD [36]. This increase in right atrium volume index possibly promotes AF [36]. Furthermore, hemodynamic overloading or stretching of the right atrium due to pulmonary hypertension may contribute to a higher prevalence of non-pulmponary vein foci from the right atrium in chronic lung disease patients [37]. Oxidative stress and inflammation represent major pathogenetic mechanisms in COPD [38,39], but have been implicated in AF initiation and perpetuation as well [40,41]. It is therefore tempting to speculate that COPD-related oxidative and inflammatory responses may promote AF development. Regarding inflammation, the C allele of polymorphic marker G(-174)C of interleukin-6 gene has been considered to be independently associated with development of AF in patients with COPD [42]. Respiratory drugs and atrial fibrillation Respiratory drugs have been shown to precipitate AF. The new use of short- and long-acting b-agonists may slightly increase the risk of AF in COPD [43]. b-Agonist medications have a potential for arrhythmogenicity because of effects on chronotropy, depolarization, repolarization, and cellular potassium distribution mediated through b-adrenergic receptors [44,45]. A single, regular dose of inhaled salbutamol was reported to enhance AV nodal conduction reflected by shortening of the AH interval and decreased atrial refractoriness [45]. The shortening of atrial refractoriness may facilitate AF induction and explain the increased incidence of the arrhythmia in COPD [46]. Anticholinergic drugs suppress parasympathetic control of heart rate, which is associated with an increased incidence of tachyarrhythmias [47]. The Lung Health Study investigators reported a relative risk for hospitalizations due to supraventricular tachycardia of 4.5 (95% CI: 0.97–20.8) associated with use of shortacting inhaled ipratropium versus placebo [48]. Ogale et al. also reported an elevated risk of dysrhythmia associated with the use of ipratropium [49], however these findings were not substantiated in the randomized controlled trials of tiotropium [50–53]. Methylxanthine agents, such as theophylline and aminophylline, have also been shown to precipitate AF [54]. The responsible mechanisms include depolarization effects and electrolyte depletion with increased excretion of potassium and magnesium through the urine [55]. Theophylline causes significant reductions in AV and His-Purkinje conduction intervals, sinoatrial conduction time, corrected sinus node recovery time, shortest atrial pacing interval producing 1:1 AV conduction and atrial effective refractory period (ERP), but does not affect intraatrial conduction interval or ventricular ERP [56]. In a case control study, short-term use of theophylline was associated with increased risk of AF [54]. Doxofylline has similar efficacy to theophylline, but appears to have a better safety profile [57]. Current glycocorticoid use was associated with an almost 2-fold increased risk of AF [58]. Despite the fact that no increased risk of arrhythmias overall was found among users of inhaled steroids, oral steroids were associated with AF [54]. Several mechanisms seem to be involved in the development of AF in patients treated with corticosteroids. Long-term glucocorticoid use has been associated with increased risk of atherosclerosis, hypertension,
Please cite this article in press as: Goudis CA. Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. J Cardiol (2017), http://dx.doi.org/10.1016/j.jjcc.2016.12.013
G Model
JJCC-1450; No. of Pages 7 4
C.A. Goudis / Journal of Cardiology xxx (2016) xxx–xxx
Fig. 1. Graphic representation of the main pathophysiological mechanisms linking chronic obstructive pulmonary disease (COPD) and atrial fibrillation.
diabetes mellitus, left atrial enlargement, heart failure, and ischemic heart disease, conditions that are well-known risk factors for AF [58]. It has also been postulated that high-dose corticosteroids mediate potassium efflux via a direct effect on the cell membrane inducing arrhythmias [59]. Moreover, the increased AF risk, especially in new high-dose users, suggests that corticosteroids may have a direct arrhythmogenic effect [59]. The pathophysiological mechanisms implicating COPD in AF are presented in Fig. 1. Prognostic significance of atrial fibrillation in chronic obstructive pulmonary disease and vice versa It is of utmost importance to take into account the incidence of AF in COPD patients. BODE Index is a multidimensional grading system that evaluates body mass index, measure of airflow obstruction, dyspnea score, and exercise capacity in COPD patients, and predicts mortality and long-term outcomes [60]. Subjects with higher scores in BODE index have a significantly greater prevalence of arrhythmias, namely supraventricular tachycardia, AF and atrial flutter [60]. Increased BODE index has been associated with impaired left ventricular and right ventricular mechanics in patients with COPD [61,62]. Five strongest predictors of mortality (extended MRC Dyspnoea Score, eosinopenia, consolidation, acidemia, and AF) were combined to form the Dyspnoea, Eosinopenia, Consolidation, Acidaemia, and atrial Fibrillation (DECAF) Score in COPD patients [63]. DECAF Score shows excellent discrimination for mortality and has performed more strongly than other clinical prediction tools [63]. On the other hand, the presence of COPD in AF patients seems to have a specific impact on AF progression, success of cardioversion, ablation outcomes, and mortality. Hypertension, age, previous stroke or transient ischemic attack, COPD, and heart failure are independent predictors of AF progression [64]. Based on these parameters, de Vos et al. developed the HATCH score (an acronym for Hypertension, Age, previous Transient ischemic attack or stroke, COPD, and Heart failure), that independently predicts AF progression [64]. As the HATCH score correlates with the occurrence of AF, it may be used to select patients for intensified ECG monitoring [65]. HATCH score can also be used as predictor of new-onset AF after typical atrial flutter ablation [66] or after coronary artery bypass grafting [67], and is useful in predicting short-term success of AF electrical cardioversion at early stages
[68]. Notably, the score can be used for stroke risk assessment, as none of the patients with a low HATCH score was proved to suffer a stroke [65]. In a recent study, however, Kochha¨user et al. reported that HATCH score is a poor predictor of AF progression, whereas left atrial diameter of more than 45 mm and heart failure are strong and independent predictors [69]. The Euro Heart Survey on AF aimed to provide insight into the present-day cardioversion of AF in ‘‘real life’’ patients and identify predictors for both immediate and long-term success. Absence of COPD predicts successful electrical cardioversion and sinus rhythm maintenance at 1-year follow-up [70]. Studies have also evaluated the efficacy and safety of managing AF with radiofrequency catheter ablation in COPD patients. Roh et al. investigated the electroanatomic alterations in pulmonary veins in chronic lung disease patients with AF and assessed their effect on the outcomes of catheter ablation [37]. They reported that catheter ablation has a comparable success rate to that of patients with normal lung function [37]. In another study, Gu et al. aimed to investigate the impact of COPD on outcomes of catheter ablation in patients with AF in terms of recurrence and quality of life [71]. Despite the fact that the presence of COPD predicted higher recurrence after single-catheter ablation in AF patients, significant improvements in quality of life were observed in the postablation COPD population [71]. The presence of COPD may also increase the risk of ischemic stroke in subjects with AF [72]. Nadeem et al. reported that AF plus COPD is a stronger predictor of ischemic cerebrovascular accident than AF only or COPD only [72]. In the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot), COPD was proved to be highly prevalent in European AF patients, and is associated with higher rates of cardiovascular death, all-cause death, and the composite outcome of any thromboembolic event/bleeding/cardiovascular death [73]. Similarly, Huang et al. reported that the presence of COPD in patients with AF is an independent risk factor for 1-year allcause and cardiovascular mortality [74]. In addition, data from the ROCKET AF [75] and the ARISTOTLE trial [76] showed that COPD is strongly associated with all-cause mortality in AF. The Atrial Fibrillation in the Emergency Room (AFTER) Study, sought to derive and validate a complex and a simplified model that predicts mortality in emergency department patients with AF [77]. Both the complex and simplified instrument that included COPD as a risk variable have been shown to predict mortality after an emergency visit for AF [77].
Please cite this article in press as: Goudis CA. Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. J Cardiol (2017), http://dx.doi.org/10.1016/j.jjcc.2016.12.013
G Model
JJCC-1450; No. of Pages 7 C.A. Goudis / Journal of Cardiology xxx (2016) xxx–xxx
Antiarrhythmic therapy and interventions for atrial fibrillation in chronic obstructive pulmonary disease Treatment of COPD in patients with concomitant AF should be the same as those without AF [78]. Available evidence suggests an overall acceptable safety profile for using long-acting b-agonists, anticholinergics, and inhaled corticosteroids [79,80]. On the contrary, caution is advised when using short-acting b-agonists [45,81] and theophylline [82,83], which may precipitate AF and worsen ventricular rate control. In patients with COPD who develop AF, treatment of the underlying pulmonary disease and correction of hypoxia and acid-base imbalance are of primary importance and represent first-line therapy [84]. Propafenone and adenosine should be used with caution in patients with significant bronchospasm, while they can safely be used in patients with COPD [84]. Diltiazem and verapamil are often tolerated and effective [84]. Amiodarone [85] or digoxin in combination with calcium channel blockers [86] can also be used. Early prophylactic amiodarone administration in patients with COPD subjected to coronary artery bypass grafting has been shown to reduce AF [87]. The use of b-blockers in patients with COPD and co-morbid cardiovascular disease has been controversial, and as a result they are under-prescribed despite increasing evidence to support their use as safe and efficacious [88]. Current evidence supports that COPD is not a contraindication for cardioselective b-blocker therapy [89,90]. b-Blocker use in patients with COPD may not only decrease the risk of overall mortality, but also reduce the risk of COPD exacerbations [91]. Direct-current cardioversion should be attempted in patients with pulmonary disease who become hemodynamically unstable as a consequence of new-onset AF [92]. In patients refractory to drug therapy, AV nodal ablation and ventricular pacing may be considered in order to control ventricular rate [92]. AF ablation was proved to be efficient and safe, and improves quality of life in COPD [71,93]. However, more studies with large sample size and long-term follow-up are needed to evaluate the efficacy and safety in managing AF with catheter ablation, as well as with different types of operation in COPD [94]. Conclusion An increasing body of evidence indicates that COPD is associated with AF. The presence of AF in COPD has significant impact on mortality, while the presence of COPD in AF has a specific impact on AF progression, success of cardioversion, ablation outcomes, and mortality. A complete elucidation of the pathophysiological mechanisms implicating COPD in AF, will offer the possibility for better therapeutic options and reduction of mortality in these patients. Treatment of the underlying pulmonary disease and correction of hypoxia and acid-base imbalance represents first-line therapy for COPD patients who develop AF. bBlockers have been traditionally contraindicated in COPD, however, recent evidence suggests that cardioselective b-blockers are safe and reduce COPD exacerbations and mortality. AF ablation can be performed safely in COPD and improves quality of life, but large studies are missing.
[2]
[3]
[4] [5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17] [18]
[19]
[20]
[21]
[22]
[23]
Conflict of interest
[24]
None. [25]
References [1] Vestbo J, Hurd SS, Agustı´ AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic
[26]
5
obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347–65. Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, Nair H, Gasevic D, Sridhar D, Campbell H, Chan KY, Sheikh A, Rudan I. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health 2015;5:020415. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/ Paisley study. Am J Med 2002;113:359–64. Beyerbach DM, Zipes DP. Mortality as an endpoint in atrial fibrillation. Heart Rhythm 2004;1:8–18. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003;21:1012–6. Sidney S, Sorel M, Quesenberry Jr CP, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005;128:2068–75. Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991–1999. COPD 2005;2:35–41. Shibata Y, Watanabe T, Osaka D, Abe S, Inoue S, Tokairin Y, Igarashi A, Yamauchi K, Kimura T, Kishi H, Aida Y, Nunomiya K, Nemoto T, Sato M, Konta T, et al. Impairment of pulmonary function is an independent risk factor for atrial fibrillation: the Takahata study. Int J Med Sci 2011;8:514–22. Li J, Agarwal SK, Alonso A, Blecker S, Chamberlain AM, London SJ, Loehr LR, McNeill AM, Poole C, Soliman EZ, Heiss G. Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2014;129:971–80. Johnson LS, Juhlin T, Engstro¨m G, Nilsson PM. Reduced forced expiratory volume is associated with increased incidence of atrial fibrillation: the Malmo Preventive Project. Europace 2014;16:182–8. Chahal H, Heckbert SR, Barr RG, Bluemke DA, Jain A, Habibi M, Alonso A, Kronmal R, Jacobs Jr DR, Lima JA, Watson KE, Liu K, Smith LJ, Greenland P. Ability of reduced lung function to predict development of atrial fibrillation in persons aged 45 to 84 years (from the Multi-Ethnic Study of AtherosclerosisLung Study). Am J Cardiol 2015;115:1700–4. Konecny T, Park JY, Somers KR, Konecny D, Orban M, Soucek F, Parker KO, Scanlon PD, Asirvatham SJ, Brady PA, Rihal CS. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol 2014;114:272–7. Gec¸men C¸, Babu¨r Gu¨ler G, Erdog˘an E, Hatipog˘lu S, Gu¨ler E, Yılmaz F, Unkun T, ¨,O ¨ zdemir N. SYNTAX Cap M, Bengi Bakal R, Bayram T, Deniz Acar R, Candan O score predicts postoperative atrial fibrillation in patients undergoing on-pump isolated coronary artery bypass grafting surgery. Anatol J Cardiol 2016;16: 655–61. Cerit L, Duygu H, Gulsen K, Kemal HS, Ozcem B, Balcioglu O, Gunsel A, Tosun O, Emren V. Is SYNTAX score predictive of atrial fibrillation after on-pump coronary artery bypass graft surgery? Korean Circ J 2016;46:798–803. Mita N, Kuroda M, Miyoshi S, Saito S. Association of preoperative right and left ventricular diastolic dysfunction with postoperative atrial fibrillation in patients undergoing lung surgery: a prospective observational study. J Cardiothorac Vasc Anesth 2016 [Epub ahead of print]. Terzano C, Romani S, Conti V, Paone G, Oriolo F, Vitarelli A. Atrial fibrillation in the acute, hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci 2014;18:2908–17. Krause PC, Inoue H, Zipes DP. Electrophysiologic alterations produced by hypoxia in the canine heart. Am Heart J 1989;117:550–61. Stevenson IH, Roberts-Thomson KC, Kistler PM, Edwards GA, Spence S, Sanders P, Kalman JM. Atrial electrophysiology is altered by acute hypercapnia but not hypoxemia: implications for promotion of atrial fibrillation in pulmonary disease and sleep apnea. Heart Rhythm 2010;7:1263–70. Lammers WJ, Kirchhof C, Bonke FI, Allessie MA. Vulnerability of rabbit atrium to reentry by hypoxia. Role of inhomogeneity in conduction and wavelength. Am J Physiol 1992;262:H47–55. Ogi H, Nakano Y, Niida S, Dote K, Hirai Y, Suenari K, Tonouchi Y, Oda N, Makita Y, Ueda S, Kajihara K, Imai K, Sueda T, Chayama K, Kihara Y. Is structural remodeling of fibrillated atria the consequence of tissue hypoxia? Circ J 2010;74:1815–21. Xu Y, Sharma D, Du F, Liu Y. The role of Toll-like receptor 2 and hypoxiainduced transcription factor-1alpha in the atrial structural remodeling of nonvalvular atrial fibrillation. Int J Cardiol 2013;168:2940–1. Su F, Zhang W, Chen Y, Ma L, Zhang H, Wang F. Significance of hypoxiainducible factor-1a expression with atrial fibrosis in rats induced with isoproterenol. Exp Ther Med 2014;8:1677–82. Stewart AG, Waterhouse JC, Howard P. The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD. Respir Med 1995;89:79–84. Sievi NA, Clarenbach CF, Camen G, Rossi VA, van Gestel AJ, Kohler M. High prevalence of altered cardiac repolarization in patients with COPD. BMC Pulm Med 2014;14:55. Mandyam MC, Soliman EZ, Alonso A, Dewland TA, Heckbert SR, Vittinghoff E, Cummings SR, Ellinor PT, Chaitman BR, Stocke K, Applegate WB, Arking DE, Butler J, Loehr LR, Magnani JW, et al. The QT interval and risk of incident atrial fibrillation. Heart Rhythm 2013;10:1562–8. Nguyen KT, Gladstone RA, Dukes JW, Nazer B, Vittinghoff E, Badhwar N, Vedantham V, Gerstenfeld EP, Lee BK, Lee RJ, Tseng ZH, Olgin JE, Scheinman
Please cite this article in press as: Goudis CA. Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. J Cardiol (2017), http://dx.doi.org/10.1016/j.jjcc.2016.12.013
G Model
JJCC-1450; No. of Pages 7 C.A. Goudis / Journal of Cardiology xxx (2016) xxx–xxx
6
[27]
[28]
[29]
[30] [31]
[32]
[33]
[34]
[35]
[36]
[37]
[38] [39]
[40] [41] [42]
[43]
[44]
[45] [46]
[47] [48]
[49] [50]
[51] [52]
[53]
[54]
MM, Marcus GM, The QT. interval as a noninvasive marker of atrial refractoriness. Pacing Clin Electrophysiol 2016 [Epub ahead of print]. Caglar IM, Dasli T, Turhan Caglar FN, Teber MK, Ugurlucan M, Ozmen G. Evaluation of atrial conduction features with tissue Doppler imaging in patients with chronic obstructive pulmonary disease. Clin Res Cardiol 2012;101:599–606. Acar G, Kahraman H, Akkoyun M, Kilinc M, Zencir C, Yusufoglu E, Dirnak I, Sahin H, Olmez S, Akcay A, Ardic I. Evaluation of atrial electromechanical delay and its relationship to inflammation and oxidative stress in patients with chronic obstructive pulmonary disease. Echocardiography 2014;31:579–85. Tu¨kek T, Yildiz P, Akkaya V, Karan MA, Atilgan D, Yilmaz V, Korkut F. Factors associated with the development of atrial fibrillation in COPD patients: the role of P-wave dispersion. Ann Noninvasive Electrocardiol 2002;7:222–7. Bhatt SP, Nanda S, Kintzer JS. Arrhythmias as trigger for acute exacerbations of chronic obstructive pulmonary disease. Respir Med 2012;106:1134–8. Hayashi H, Miyamoto A, Kawaguchi T, Naiki N, Xue JQ, Matsumoto T, Murakami Y, Horie M. P-pulmonale and the development of atrial fibrillation. Circ J 2014;78:329–37. Buzea CA, Dan AR, Delcea C, Balea MI, Gologanu D, Dobranici M, Popescu RA, Dan GA. P wave signal-averaged electrocardiography in patients with chronic obstructive pulmonary disease. Rom J Intern Med 2015;53:315–20. Baum C, Ojeda FM, Wild PS, Rzayeva N, Zeller T, Sinning CR, Pfeiffer N, Beutel M, Blettner M, Lackner KJ, Blankenberg S, Mu¨nzel T, Rabe KF, Schnabel RB, Gutenberg Health Study investigators. Subclinical impairment of lung function is related to mild cardiac dysfunction and manifest heart failure in the general population. Int J Cardiol 2016;218:298–304. Eweda I, Hamada G. Concordance between Doppler and pulsed-wave Doppler tissue imaging in estimation of the degree of left ventricular dysfunction and correlating it to the degree of chronic obstructive pulmonary disease. J Saudi Heart Assoc 2016;28:15–21. Caram LM, Ferrari R, Naves CR, Tanni SE, Coelho LS, Zanati SG, Minicucci MF, Godoy I. Association between left ventricular diastolic dysfunction and severity of chronic obstructive pulmonary disease. Clinics 2013;68:772–6. Agoston-Coldea L, Petrovai D, Mihalcea I, Revnic R, Mocan T, Lupu S. Right atrium volume index in patients with secondary pulmonary hypertension due to chronic obstructive pulmonary disease. Acta Cardiol Sin 2015;31:325–36. Roh SY, Choi JI, Lee JY, Kwak JJ, Park JS, Kim JB, Lim HE, Kim YH. Catheter ablation of atrial fibrillation in patients with chronic lung disease. Circ Arrhythm Electrophysiol 2011;4:815–22. Kirkham PA, Barnes PJ. Oxidative stress in COPD. Chest 2013;144:266–73. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574–80. Huang CX, Liu Y, Xia WF, Tang YH, Huang H. Oxidative stress: a possible pathogenesis of atrial fibrillation. Med Hypotheses 2009;72:466–7. Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 2015;79:495–502. Volchkova EA, Nikitin AG, Zotova IV, Zateyshchikova AA, Shavrin IV, Safaryan VI, Nosikov VV, Zateyshchikov DA. Atrial fibrillation in patients with chronic obstructive pulmonary disease is associated with polymorphism of interleukin 6 gene. Kardiologiia 2015;55:31–6. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: Part 2: reassessment in the larger Quebec cohort. Chest 2012;142:305–11. Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A, Matera MG. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998;114:411–5. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004;125:2309–21. Kallergis EM, Manios EG, Kanoupakis EM, Schiza SE, Mavrakis HE, Klapsinos NK, Vardas PE. Acute electrophysiologic effects of inhaled salbutamol in humans. Chest 2005;127:2057–63. Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and proischaemic effects of inhaled anticholinergic me-dications. Thorax 2013;68:114–6. Anthonisen NR, Connett JE, Enright PL, Manfreda J, Lung Health Study Research Group. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med 2002;166:333–9. Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest 2010;137:13–9. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543–54. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130:1695–703. Hohlfeld JM, Furtwaengler A, Ko¨nen-Bergmann M, Wallenstein G, Walter B, Bateman ED. Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials. Int J Clin Pract 2015;69:72–80. Wedzicha JA, Dahl R, Buhl R, Schubert-Tennigkeit A, Chen H, D’Andrea P, Fogel R, Banerji D. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med 2014;108:1498–507. Huerta C, Lanes SF, Garcı´a Rodrı´guez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005;16:360–6.
[55] Wood-Baker R, Cochrane B, Naughton MT. Cardiovascular mortality and morbidity in chronic obstructive pulmonary disease: the impact of bronchodilator treatment. Intern Med J 2010;40:94–101. [56] Eiriksson Jr CE, Writer SL, Vestal RE. Theophylline-induced alterations in cardiac electrophysiology in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1987;135:322–6. [57] Shukla D, Chakraborty S, Singh S, Mishra B. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Pharmacother 2009;10:2343–56. [58] Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sørensen HT. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case–control study. Arch Intern Med 2009;169:1677–83. [59] van der Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JC, Kingma JH, Sturkenboom MC, Stricker BH. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006;166:1016–20. [60] Grabicki M, Parysek H, Batura-Gabryel H, Brodnicka I. Comorbidities as an element of multidimensional prognostic assessment of patients with chronic obstructive pulmonary disease. J Physiol Pharmacol 2008;59(Suppl 6): 297–301. [61] Kalaycıog˘lu E, Go¨kdeniz T, Aykan AC¸, Hatem E, Gu¨rsoy MO, Toksoy F, Dursun I, C¸elik S. Evaluation of left ventricular function and its relationship with multidimensional grading system (BODE index) in patients with COPD. COPD 2015;12:568–74. [62] Go¨kdeniz T, Kalaycıog˘lu E, Boyacı F, Aykan AC¸, Gu¨rsoy MO, Hatem E, Bo¨rekc¸i A, Karabag Y, Altun S. The BODE index, a multidimensional grading system, reflects impairment of right ventricle functions in patients with chronic obstructive pulmonary disease: a speckle-tracking study. Respiration 2014; 88:223–33. [63] Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 2012;67: 970–6. [64] de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, van den Heijkant AC, Allessie MA, Crijns HJ. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010;55:725–31. [65] Tischer TS, Schneider R, Lauschke J, Diedrich D, Kundt G, Ba¨nsch D. Prevalence of atrial fibrillation and the HATCH score: Intensified monitoring of patients with high HATCH score. Herz 2015;40:803–8. [66] Chen K, Bai R, Deng W, Gao C, Zhang J, Wang X, Wang S, Fu H, Zhao Y, Zhang J, Dong J, Ma C. HATCH score in the prediction of new-onset atrial fibrillation after catheter ablation of typical atrial flutter. Heart Rhythm 2015;12:1483–9. [67] Emren V, Aldemir M, Duygu H, Kocabas¸ U, Tecer E, Cerit L, Erdil N. Usefulness of HATCH score as a predictor of atrial fibrillation after coronary artery bypass graft. Kardiol Pol 2016 [Epub ahead of print]. [68] Emren SV, Kocabas¸ U, Duygu H, Levent F, S¸ims¸ek EC¸, Yapan Emren Z, Tu¨lu¨ce S. The role of HATCH score in predicting the success rate of sinus rhythm following electrical cardioversion of atrial fibrillation. Kardiol Pol 2016;74:978–84. [69] Kochha¨user S, Dechering DG, Trought K, Hache P, Haig-Carter T, Khaykin Y, Wulffhart Z, Pantano A, Tsang B, Eckardt L, Verma A. Predictors for progression of atrial fibrillation in patients awaiting atrial fibrillation ablation. Can J Cardiol 2016;32:1348–54. [70] Pisters R, Nieuwlaat R, Prins MH, Le Heuzey JY, Maggioni AP, Camm AJ, Crijns HJ, Euro Heart Survey Investigators. Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace 2012;14:666–74. [71] Gu J, Liu X, Tan H, Zhou L, Jiang W, Wang Y, Liu Y, Gu J. Impact of chronic obstructive pulmonary disease on procedural outcomes and quality of life in patients with atrial fibrillation undergoing catheter ablation. J Cardiovasc Electrophysiol 2013;24:148–54. [72] Nadeem R, Sharieff A, Tanna S, Sidhu H, Molnar J, Nadeem A. Potential augmentation of the risk of ischemic cerebrovascular accident by chronic obstructive pulmonary disease in patients with atrial fibrillation. J Stroke Cerebrovasc Dis 2015;24:1893–6. [73] Proietti M, Laroche C, Drozd M, Vijgen J, Cozma DC, Drozdz J, Maggioni AP, Boriani G, Lip GY, EORP-AF Investigators. Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. Am Heart J 2016;181:83–91. [74] Huang B, Yang Y, Zhu J, Liang Y, Zhang H, Tian L, Shao X, Wang J. Clinical characteristics and prognostic significance of chronic obstructive pulmonary disease in patients with atrial fibrillation: results from a multicenter atrial fibrillation registry study. J Am Med Dir Assoc 2014;15:576–81. [75] Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc 2016;5:e002197. [76] Durheim MT, Cyr DD, Lopes RD, Thomas LE, Tsuang WM, Gersh BJ, Held C, Wallentin L, Granger CB, Palmer SM, Al-Khatib SM. Chronic obstructive pulmonary disease in patients with atrial fibrillation: insights from the ARISTOTLE trial. Int J Cardiol 2016;202:589–94. [77] Atzema CL, Dorian P, Fang J, Tu JV, Lee DS, Chong AS, Austin PC. A Clinical decision instrument for 30-day death after an emergency department visit for atrial fibrillation: The Atrial Fibrillation in the Emergency Room (AFTER) Study. Ann Emerg Med 2015;66:658–68. e6.
Please cite this article in press as: Goudis CA. Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. J Cardiol (2017), http://dx.doi.org/10.1016/j.jjcc.2016.12.013
G Model
JJCC-1450; No. of Pages 7 C.A. Goudis / Journal of Cardiology xxx (2016) xxx–xxx [78] Roversi S, Fabbri LM, Sin DD, Hawkins NM, Agustı´ A. Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care. Am J Respir Crit Care Med 2016;194:1319–36. [79] Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Crim C, Willits LR, Yates JC, Vestbo J, TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010;65:719–25. [80] Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P, TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013;369:1491–501. [81] Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: Part 1: Saskatchewan cohort study. Chest 2012;142:298–304. [82] Sessler CN, Cohen MD. Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study. Chest 1990;98: 672–8. [83] Ohta K, Fukuchi Y, Grouse L, Mizutani R, Rabe KF, Rennard SI, Zhong N-S. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respir Med 2004;98:1016–24. [84] Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC endorsed by the European Stroke Organisation (ESO). Eur Heart J 2016. pii:ehw210. [85] Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M, Siostrzonek P, Heinz G. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001;29: 1149–53.
7
[86] Goldman S, Probst P, Selzer A, Cohn K. Inefficacy of ‘‘therapeutic’’ serum levels of digoxin in controlling the ventricular rate in atrial fibrillation. Am J Cardiol 1975;35:651–5. [87] Kuralay E, Cingo¨z F, Kilic¸ S, Bolcal C, Gu¨nay C, Demirkilic¸ U, Tatar H. Supraventricular tachyarrythmia prophylaxis after coronary artery surgery in chronic obstructive pulmonary disease patients (early amiodarone prophylaxis trial). Eur J Cardiothorac Surg 2004;25:224–30. [88] Neef PA, McDonald CF, Burrell LM, Irving LB, Johnson DF, Steinfort DP. Betablockers are under-prescribed in patients with chronic obstructive pulmonary disease and co-morbid cardiac disease. Intern Med J 2016;46:1336–40. [89] Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;(4): CD003566. [90] Ni Y, Shi G, Wan H. Use of cardioselective b-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Res 2012;40:2051–65. [91] Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLOS ONE 2014;9:e113048. [92] January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland Jr JC, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1–76. [93] Kumar N, Pison L, La Meir M, Maessen J, Crijns HJ. Hybrid approach to atrial fibrillation ablation using bipolar radiofrequency devices epicardially and cryoballoon endocardially. Interact Cardiovasc Thorac Surg 2014;19:590–4. [94] Huang B, Yang Y. Radiofrequency catheter ablation of atrial fibrillation in patients with chronic obstructive pulmonary disease: opportunity and challenge: response to Dr. Kumar’s comment. J Am Med Dir Assoc 2015;16:83–4.
Please cite this article in press as: Goudis CA. Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. J Cardiol (2017), http://dx.doi.org/10.1016/j.jjcc.2016.12.013